`Approved for use through 01f31I2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`_
`_
`Application Number
`
`H0003965DIV1E
`
`Title of Invention
`
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS
`USING SAME
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2
`
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`Legal Name
`
`1
`
`Prefix Given Name
`
`Mr.
`
`Rajiv
`
`Middle Name
`
`R.
`
`Family Name
`
`Singh
`
`Residence Information (Select One) @ US Residency Q Non US Residency Q Active US Military Service
`City
`Getzville
`StateIProvince
`NY
`country of Residencei | US
`
`Mailing Address of Inventor:
`
`18 Foxfire Drive
`
`Address 1
`
`Address 2
`
`City
`
`Postal Code
`
`Inventor
`
`2
`
`Legal Name
`
`StateIProvince
`
`Country i
`
`US
`
`Given Name
`
`Middle Name
`
`Family Name
`
`Residence Information (Select One) Q US Residency Q Non US Residency Q Active US Military Service
`City
`Amherst
`| StatelProvince
`NY
`Country Qf Residence | US
`
`Mailing Address of Inventor:
`
`136 Larkspur Lane
`
`5tate'Pr°vince
`
`Address 1
`
`Address 2
`
`Postal Code
`
`Inventor
`
`3
`
`Legal Name
`
`Fa'""v"=""e
`"'idd'e"a-"8
`a— Shankbnd
`Residence Information (Select One) Q US Residency Q Non US Residency Q Active US Military Service
`
`EFS Web 2.2.11
`
`Page 1 of 8
`
`Arkema Exhibit 1046
`
`
`
`PTO/AIAI14 (12-13)
`Approved for use through 0‘lf31I20‘l4. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Papenrvork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`H0003965DIV1E
`
`Title of Invention
`
`Application Number
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS
`USING SAME
`
`City
`
`Buffalo
`
`Statei'Province
`
`NY
`
`country ofRe5jdencel
`
`US
`
`Mailing Address of Inventor:
`
`Address 1
`
`Address 2
`
`6 Horizon Court
`
`City
`
`Buffalo
`
`StateIProvince
`
`US
`07869
`Postal Code
`Inventor Information blocks may be
`All
`Inventors Must Be Listed - Additional
`generated within this form by selecting the Add button.
`
`Correspondence Information:
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`|:| An Address is being provided for the correspondence Information of this application.
`
`Customer Number
`
`91970
`
`Email Address
`
`Add Email
`
`Application Information:
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND
`SYSTEMS USING SAME
`
`Title of the Invention
`
`Attorney Docket Number HOOO3965D|V1E
`
`Small Entity Status Claimed
`
`|:|
`
`Application Type
`
`Nonprovisional
`
`Subject Matter
`Utility
`Total Number of Drawing Sheets (if any) — Suggested Figure for Publication (if any)
`Filing By Reference:
`
`Only complete this section when filing an application by reference under 35 U.S.C. 1l1(c) and 37 CFR1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information'' and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`Application number of the previously
`filed application
`
`Filing date (YYW—MM—DD)
`
`Intellectual Property Authority or Country I
`
`Publication Information:
`
`|:| Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request N012 ‘I20 Publish. I hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`EFS Web 2.2.11
`
`Page 2 of 8
`
`
`
`PTO/AIAI14 (12-13)
`Approved for use through 01731112014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Papenrvork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`H0003965DIV1E
`
`Title of Invention
`
`Application Number
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS
`USING SAME
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`Please Select One:
`Customer Number
`
`@ Customer Number
`91970
`
`0 US Patent Practitioner 0 Limited Recognition (37 CFR 11.9)
`
`Domestic BenefitINational Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C.119(e),120. 121. or 365(c) or indicate National Stage
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the application number blank.
`
`Prior Application Status
`
`Pending
`
`Application Number
`
`Continuity Type
`Division of
`
`Prior Application Number
`13844206
`
`Filing Date (YYYY-MM-DD)
`2013-03-15
`
`Prior Application Status
`
`Pending
`
`Application Number
`13844206
`
`Continuity Type
`
`Prior Application Number
`11847192
`
`Filing Date (YYYY-MM-DD}
`2007-08-29
`
`Prior Application Status
`Application
`Number
`11847192
`
`Continuity Type
`
`Prior Application Status
`
`Expired
`
`Prior Application
`Number
`10837525
`
`Filing Date
`(YYYY-MM-DD)
`2004-04-29
`
`Pater” N“"‘be'
`7279451
`
`ISSUE Dale
`(YYYY—MM—DD)
`2007-10-09
`
`W
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`10694273
`
`Claims benefit of provisional
`
`60421263
`
`2002-10-25
`
`Prior Application Status
`
`Expired
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD}
`
`10694273
`
`Claims benefit of provisional
`
`60421435
`
`2002-10-25
`
`Prior Application Status
`Application
`Number
`11847192
`
`Continuity Type
`
`Continuation in part of
`
`Prior Application
`Number
`10694272
`
`Filing Date
`(YYYY-MM-DD)
`2003-10-27
`
`Pater“ N“'“'°e'
`7230146
`
`ISSUE! Dale
`(YYYY-MM-DD)
`2007-06-12
`
`Patented
`
`W
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`EFS Web 2.2.11
`
`Page 3 of 8
`
`
`
`PTO/AIAI14 (12-13)
`Approved for use through 01f31I2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Papenrvork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`H0003965DIV1E
`
`.
`.
`Title of Invention
`
`Application Number
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS
`USING SAME
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U_S_C_ 119(b) and 37 CFR 1_55(d)_ When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX) ‘the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PDX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`Application Number
`
`Country l
`
`Filing Date (YYYY-MM-DD)
`
`-
`Access Codel (if applicable)
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`|:| 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`Authorization to Permit Access:
`
`|:| Authorization to Permit Access to the Instant Application by the Participating Offices
`
`EFS Web 2.2.11
`
`Page 4 of 8
`
`
`
`PTO/AIAI14 (12-13)
`Approved for use through 0173172014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Papenrvork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`H0003965DIV1E
`
`Title of Invention
`
`Application Number
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS
`USING SAME
`
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked ifthe applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application—as—filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)—(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`1
`Applicant
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`@ Assignee
`
`0 Legal Representative under 35 U.S.C. 117
`
`Q Joint Inventor
`
`0 Person to whom the inventor is obligated to assign.
`
`O Person who shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Name of the Deceased or Legally incapacitated Inventor :
`
`If the Applicant is an Organization check here.
`
`Organlzallon Name
`
`Honeywell International Inc.
`
`Mailing Address Information:
`Address 1
`101 Columbia Road
`
`Address 2
`
`City
`
`Phone Number
`
`EFS Web 2.2.11
`
`Morristown
`
`StateIProvince
`Postal Code
`
`Fax Number
`
`Page 5 of 8
`
`
`
`PTO/AIAI14 (12-13)
`Approved for use through 0113172014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Papenlvork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`H0003965DIV1E
`
`Application Number
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS
`USING SAME
`
`Title of Invention
`
`Email Address
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Add
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office_
`
`Assignee
`
`1
`
`Complete this section if assignee information, including non—app|icant assignee information, is desired to be included on the patent
`application publication . An assignee—applicant identified in the "Applicant lnformation" section will appear on the patent application
`publication as an applicant. For an assignee—applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`Middle Name
`
`Family Name
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Address 1
`
`Address 2
`
`City
`
`Phone Number
`
`Email Address
`
`StatelProvince
`
`Postal Code
`
`Fax Number
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Signature:
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications
`
`Signature
`
`/Kenneth Ma 63,839!
`
`Date (YYYY-MM-DD)
`
`2014-03-25
`
`First Name
`
`Kenneth
`
`Last Name
`
`Registration Number
`
`63839
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`EFS Web 2.2.11
`
`Page 6 of 8
`
`
`
`PTO/AIAI14 (12-13)
`Approved for use through 0‘lf31I2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Papenrvork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Attorney Docket Number
`
`H0003965DIV1E
`
`Application Data Sheet 37 CFR 1.76
`
`Title of Invention
`
`Application Number
`COMPOSITIONS CONTAINING FLUORINE SUBSTITUTED OLEFINS AND METHODS AND SYSTEMS
`USING SAME
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount oftime you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.11
`
`Page 7 of 8
`
`
`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U_S_C_ 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process andlor examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U_S_C_ 552)
`and the Privacy Act (5 U_S_C_ 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U_S_C_ 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U_S_C_ 181) and for review pursuant to the Atomic Energy Act (42 U_S_C_ 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hislher designee,
`during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records
`management practices and programs, under authority of 44 U_S_C_ 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant
`to 35 U_S_C_ 122(b) or issuance of a patent pursuant to 35 U_S_C_ 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the
`USPTO becomes aware of a violation or potential violation of law or regulation.
`
`EFS Web 2.2.11
`
`Page 8 of 8
`
`